Dermatology co Foamix mulls Nasdaq IPO
The company has developed a device for automatic measurement of urine flow.
FlowSense is a newcomer to the Tel Aviv Stock Exchange, via a merger with stock-market shell Dorot.
Two months after the merger, the merged company is trade at a market cap of NIS 92 million. Last Wednesday, FlowSense (which is still traded under the name Dorot) filed a draft prospectus for raising further capital on the Tel Aviv Stock Exchange, after a NIS 4.2 million private placement as part of the merger with Dorot.
The main shareholders in the company are investment and consultancy company Trendlines (which owns the Misgav and Mofet B'Yehuda technology incubators), the Zitelman Group, Inc. (a veteran investor in Trendlines and in companies that graduate from its incubators), a private investor by the name of Shraga Karpfen, and Zeev Bronfeld (who invested because of his links with Trendlines).
FlowSense seeks to turn a base material into gold in its case, urine. Measuring urine output is of huge medical importance, but no-one likes coming into close contact with urine. FlowSense is trying to ensure that as few doctors and nurses as possible will have to handle urine as such, and it hopes at the same time to improve the situation of patients with kidney injuries, and to save money and manpower in hospitals.
"The product does not require US Food and Drug Administration approval, because it does not come into contact with the body," says FlowSense CEO Robert Bash. "It does not need to be recognized by the insurance companies, because it is intended for use in accident and emergency rooms and on intensive care wards, where the insurance refund is received by the hospital per patient, according to his or her injury or illness, and not as a refund for specific procedures."
The product is currently on sale in Israel, and has been installed beside 100 beds in several hospitals. The company shortly intends to storm the European market, and then gradually to enter the market most important to it, the US, at first through direct market, and later on through a distributor.
Urine flow is an indicator used in all intensive care departments. At present, measurement in manual: once an hour, a nurse takes the catheter bag and estimates the urine level according to the scale marks on the bag.
"Measuring this way has many limitations," says Bash. "It is not continuous, not accurate, and manual recording leaves a lot of scope for error. Many companies, several Israel ones among them, have tried to bring to market a product for automatic urine flow measurement, but have failed on the technological level. The only one that has succeeded is Bard, but its product is big and costly."
FlowSense's technology first of all turns the urine into drops of uniform size, and then counts them as they fall into the bag, by optical means. Trendlines chairman Todd Dollinger notes that FlowSense was founded on the basis of technology from Med Dynamics. "We intend for the company to grow, including through external growth," he says. The plan is apparently to acquire more technologies for marketing using the company as a platform.
Why did you merge with a stock market shell?
"We wanted access to capital, but we don’t need NIS 30 million, which is the minimum amount that can be raised in an offering in Tel Aviv," CFO Ronen Koyfman explains.
Bash has already been through several important cross roads in the Israeli biomed industry. He was a partner in the Nitzanim and Infinity funds, and later joined serial entrepreneur Asher Shmulewitz, now an investor in Topspin Medical Inc. (TASE:TOPMD), to develop a stent for treating cerebral aneurysms.
Bash went on to join a group of entrepreneurs who founded X-Technologies, which was sold to Guidant, and together with them founded YMed, in California, which developed a treatment for bifurcated arteries. Among the investors in YMed was the late Aharon Shaked, one of the owners of 888 Holding plc (LSE:888). The company was sold to Bard, now a FlowSense competitor, about a year ago, for $35 million, with potential for further milestone payments, after a much smaller sum was invested in it.
Published by Globes [online], Israel business news - www.globes-online.com - on October 17, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
You comment was recieved and soon will be published.
Load more comments
The developer of foam-based dermatology treatments is seeking underwriters.
Can-Fite Biopharma raises $5m
The proceeds will finance clinical trials for psoriasis, glaucoma, and liver cancer treatments.
Teva switching Copaxone users to new dosage
"Bloomberg": Teva has switched 8.7% of Copaxone's multiple sclerosis patients to the 40 milligram dosage.
Immune Pharmaceuticals raises $11.7m on Nasdaq
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.